Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
ACADIA Pharmaceuticals Inc has a consensus price target of $28.09 based on the ratings of 24 analysts. The high is $42 issued by Cantor Fitzgerald on August 22, 2023. The low is $19 issued by Oppenheimer on May 6, 2024. The 3 most-recent analyst ratings were released by JP Morgan, B of A Securities, and Deutsche Bank on June 6, 2025, June 5, 2025, and May 21, 2025, respectively. With an average price target of $29.33 between JP Morgan, B of A Securities, and Deutsche Bank, there's an implied 27.54% upside for ACADIA Pharmaceuticals Inc from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
06/06/2025 | Buy Now | 30.44% | JP Morgan | Tessa Romero60% | $26 → $30 | Maintains | Overweight | Get Alert |
06/05/2025 | Buy Now | — | B of A Securities | Tazeen Ahmad56% | $18 → $23 | Maintains | Neutral | Get Alert |
05/21/2025 | Buy Now | 52.18% | Deutsche Bank | David Hoang40% | $20 → $35 | Upgrade | Hold → Buy | Get Alert |
05/20/2025 | Buy Now | 4.35% | Morgan Stanley | Jeffrey Hung51% | $20 → $24 | Maintains | Equal-Weight | Get Alert |
05/19/2025 | Buy Now | — | Mizuho | Uy Ear61% | $20 → $23 | Maintains | Neutral | Get Alert |
05/19/2025 | Buy Now | 34.78% | Baird | Joel Beatty69% | $28 → $31 | Maintains | Outperform | Get Alert |
05/19/2025 | Buy Now | 13.04% | RBC Capital | Gregory Renza50% | $26 → $26 | Reiterates | Outperform → Outperform | Get Alert |
05/19/2025 | Buy Now | 21.74% | BMO Capital | Evan David Seigerman50% | $24 → $28 | Maintains | Outperform | Get Alert |
05/19/2025 | Buy Now | 39.13% | HC Wainwright & Co. | Andrew Fein61% | $27 → $32 | Maintains | Buy | Get Alert |
05/19/2025 | Buy Now | 30.44% | Needham | Ami Fadia59% | $27 → $30 | Maintains | Buy | Get Alert |
04/28/2025 | Buy Now | -4.35% | UBS | Ashwani Verma48% | $25 → $22 | Maintains | Buy | Get Alert |
04/08/2025 | Buy Now | 21.74% | Needham | Ami Fadia59% | $28 → $28 | Reiterates | Buy → Buy | Get Alert |
03/07/2025 | Buy Now | -13.04% | Morgan Stanley | Jeffrey Hung51% | $20 → $20 | Assumes | → Equal-Weight | Get Alert |
02/27/2025 | Buy Now | 21.74% | Cantor Fitzgerald | Charles Duncan69% | $28 → $28 | Reiterates | Overweight → Overweight | Get Alert |
02/27/2025 | Buy Now | 17.39% | HC Wainwright & Co. | Andrew Fein61% | $27 → $27 | Reiterates | Buy → Buy | Get Alert |
02/27/2025 | Buy Now | 21.74% | Needham | Ami Fadia59% | $28 → $28 | Reiterates | Buy → Buy | Get Alert |
02/11/2025 | Buy Now | -4.35% | Deutsche Bank | Neena Bitritto-Garg58% | → $22 | Initiates | → Hold | Get Alert |
01/03/2025 | Buy Now | -13.04% | Guggenheim | Yatin Suneja56% | $20 → $20 | Downgrade | Buy → Neutral | Get Alert |
11/07/2024 | Buy Now | 21.74% | Needham | Ami Fadia59% | $28 → $28 | Reiterates | Buy → Buy | Get Alert |
11/07/2024 | Buy Now | 17.39% | HC Wainwright & Co. | Andrew Fein61% | $27 → $27 | Reiterates | Buy → Buy | Get Alert |
10/10/2024 | Buy Now | — | Raymond James | Danielle Brill43% | — | Reinstates | → Market Perform | Get Alert |
08/08/2024 | Buy Now | — | Citigroup | David Hoang40% | $30 → $23 | Maintains | Buy | Get Alert |
08/08/2024 | Buy Now | — | UBS | Ashwani Verma48% | $25 → $23 | Maintains | Buy | Get Alert |
08/08/2024 | Buy Now | 17.39% | HC Wainwright & Co. | Andrew Fein61% | $27 → $27 | Reiterates | Buy → Buy | Get Alert |
08/07/2024 | Buy Now | 21.74% | Needham | Ami Fadia59% | $30 → $28 | Maintains | Buy | Get Alert |
08/07/2024 | Buy Now | 21.74% | Cantor Fitzgerald | Charles Duncan69% | $37 → $28 | Maintains | Overweight | Get Alert |
08/07/2024 | Buy Now | 13.04% | RBC Capital | Gregory Renza50% | $29 → $26 | Maintains | Outperform | Get Alert |
08/07/2024 | Buy Now | -13.04% | Morgan Stanley | Jeffrey Hung51% | $28 → $20 | Downgrade | Overweight → Equal-Weight | Get Alert |
07/12/2024 | Buy Now | 21.74% | Morgan Stanley | Jeffrey Hung51% | $30 → $28 | Maintains | Overweight | Get Alert |
06/27/2024 | Buy Now | 34.78% | BMO Capital | Keith Tapper56% | → $31 | Initiates | → Outperform | Get Alert |
06/25/2024 | Buy Now | 26.09% | RBC Capital | Gregory Renza50% | $29 → $29 | Reiterates | Outperform → Outperform | Get Alert |
05/10/2024 | Buy Now | -4.35% | B of A Securities | Tazeen Ahmad56% | $26 → $22 | Maintains | Neutral | Get Alert |
05/09/2024 | Buy Now | 30.44% | Needham | Ami Fadia59% | $30 → $30 | Reiterates | Buy → Buy | Get Alert |
05/09/2024 | Buy Now | 60.87% | Cantor Fitzgerald | Charles Duncan69% | $37 → $37 | Reiterates | Overweight → Overweight | Get Alert |
05/09/2024 | Buy Now | 17.39% | HC Wainwright & Co. | Andrew Fein61% | $33 → $27 | Maintains | Buy | Get Alert |
05/09/2024 | Buy Now | 30.44% | Citigroup | David Hoang40% | $30.19 → $30 | Maintains | Buy | Get Alert |
05/09/2024 | Buy Now | -8.69% | Stifel | Paul Matteis44% | $26 → $21 | Maintains | Hold | Get Alert |
05/09/2024 | Buy Now | -8.69% | Mizuho | Uy Ear61% | $25 → $21 | Maintains | Neutral | Get Alert |
05/09/2024 | Buy Now | 21.74% | Baird | Joel Beatty69% | $31 → $28 | Maintains | Outperform | Get Alert |
05/06/2024 | Buy Now | -17.39% | Oppenheimer | Jay Olson60% | $19 → $19 | Maintains | Perform | Get Alert |
04/30/2024 | Buy Now | 17.39% | UBS | Ashwani Verma48% | $33 → $27 | Maintains | Buy | Get Alert |
04/30/2024 | Buy Now | 60.87% | Cantor Fitzgerald | Charles Duncan69% | $37 → $37 | Reiterates | Overweight → Overweight | Get Alert |
04/10/2024 | Buy Now | 60.87% | Cantor Fitzgerald | Charles Duncan69% | $37 → $37 | Reiterates | Overweight → Overweight | Get Alert |
04/09/2024 | Buy Now | 39.13% | Needham | Ami Fadia59% | $32 → $32 | Reiterates | Buy → Buy | Get Alert |
03/25/2024 | Buy Now | 8.7% | JP Morgan | Tessa Romero60% | $29 → $25 | Maintains | Overweight | Get Alert |
03/13/2024 | Buy Now | 30.44% | Morgan Stanley | Jeffrey Hung51% | $40 → $30 | Maintains | Overweight | Get Alert |
03/12/2024 | Buy Now | 31.26% | Citigroup | David Hoang40% | $38 → $30.19 | Maintains | Buy | Get Alert |
03/12/2024 | Buy Now | 30.44% | RBC Capital | Gregory Renza50% | $35 → $30 | Maintains | Outperform | Get Alert |
03/12/2024 | Buy Now | 8.7% | Mizuho | Uy Ear61% | $39 → $25 | Downgrade | Buy → Neutral | Get Alert |
03/12/2024 | Buy Now | 69.57% | JMP Securities | Jason Butler52% | $44 → $39 | Maintains | Outperform | Get Alert |
03/12/2024 | Buy Now | 60.87% | Cantor Fitzgerald | Charles Duncan69% | $42 → $37 | Maintains | Overweight | Get Alert |
03/12/2024 | Buy Now | 34.78% | Baird | Joel Beatty69% | $40 → $31 | Maintains | Outperform | Get Alert |
03/12/2024 | Buy Now | -17.39% | Oppenheimer | Jay Olson60% | $25 → $19 | Maintains | Perform | Get Alert |
03/12/2024 | Buy Now | 30.44% | B of A Securities | Tazeen Ahmad56% | $33 → $30 | Maintains | Neutral | Get Alert |
03/12/2024 | Buy Now | 43.48% | Canaccord Genuity | Sumant Kulkarni43% | $40 → $33 | Maintains | Buy | Get Alert |
03/12/2024 | Buy Now | 43.48% | HC Wainwright & Co. | Andrew Fein61% | → $33 | Reiterates | Buy → Buy | Get Alert |
03/12/2024 | Buy Now | 39.13% | Needham | Ami Fadia59% | $36 → $32 | Maintains | Buy | Get Alert |
03/01/2024 | Buy Now | 26.09% | JP Morgan | Tessa Romero60% | $32 → $29 | Maintains | Overweight | Get Alert |
02/28/2024 | Buy Now | 43.48% | HC Wainwright & Co. | Andrew Fein61% | $33 → $33 | Reiterates | Buy → Buy | Get Alert |
02/28/2024 | Buy Now | 82.61% | Cantor Fitzgerald | Charles Duncan69% | $42 → $42 | Reiterates | Overweight → Overweight | Get Alert |
02/28/2024 | Buy Now | 52.18% | RBC Capital | Gregory Renza50% | $36 → $35 | Maintains | Outperform | Get Alert |
02/28/2024 | Buy Now | 69.57% | Mizuho | Uy Ear61% | $40 → $39 | Maintains | Buy | Get Alert |
02/28/2024 | Buy Now | 56.52% | Needham | Ami Fadia59% | $37 → $36 | Maintains | Buy | Get Alert |
02/07/2024 | Buy Now | 82.61% | JMP Securities | Jason Butler52% | $42 → $42 | Reiterates | Market Outperform → Market Outperform | Get Alert |
02/05/2024 | Buy Now | 8.7% | Oppenheimer | Jay Olson60% | → $25 | Reiterates | Perform → Perform | Get Alert |
02/02/2024 | Buy Now | 82.61% | Cantor Fitzgerald | Charles Duncan69% | $42 → $42 | Reiterates | Overweight → Overweight | Get Alert |
01/30/2024 | Buy Now | 73.91% | Baird | Joel Beatty69% | → $40 | Initiates | → Outperform | Get Alert |
01/24/2024 | Buy Now | 60.87% | Needham | Joseph Stringer61% | → $37 | Upgrade | Hold → Buy | Get Alert |
12/29/2023 | Buy Now | 73.91% | Mizuho | Uy Ear61% | $35 → $40 | Maintains | Buy | Get Alert |
12/19/2023 | Buy Now | 73.91% | Morgan Stanley | Jeffrey Hung51% | $31 → $40 | Upgrade | Equal-Weight → Overweight | Get Alert |
12/18/2023 | Buy Now | 17.39% | Stifel | Paul Matteis44% | $25 → $27 | Maintains | Hold | Get Alert |
12/14/2023 | Buy Now | 82.61% | Cantor Fitzgerald | Charles Duncan69% | $42 → $42 | Reiterates | Overweight → Overweight | Get Alert |
12/14/2023 | Buy Now | 8.7% | Deutsche Bank | Neena Bitritto-Garg58% | → $25 | Downgrade | Buy → Hold | Get Alert |
12/13/2023 | Buy Now | 65.22% | Citigroup | David Hoang40% | → $38 | Initiates | → Buy | Get Alert |
12/12/2023 | Buy Now | 8.7% | Deutsche Bank | Neena Bitritto-Garg58% | → $25 | Initiates | → Buy | Get Alert |
11/06/2023 | Buy Now | 73.91% | Canaccord Genuity | Sumant Kulkarni43% | $38 → $40 | Maintains | Buy | Get Alert |
11/06/2023 | Buy Now | 52.18% | Mizuho | Uy Ear61% | $20 → $35 | Upgrade | Neutral → Buy | Get Alert |
11/03/2023 | Buy Now | 82.61% | JMP Securities | Jason Butler52% | $39 → $42 | Maintains | Market Outperform | Get Alert |
11/03/2023 | Buy Now | 43.48% | RBC Capital | Gregory Renza50% | $32 → $33 | Maintains | Outperform | Get Alert |
11/03/2023 | Buy Now | 34.78% | Morgan Stanley | Jeffrey Hung51% | $30 → $31 | Maintains | Equal-Weight | Get Alert |
10/17/2023 | Buy Now | 43.48% | UBS | Ashwani Verma48% | → $33 | Initiates | → Buy | Get Alert |
10/10/2023 | Buy Now | 39.13% | JP Morgan | Tessa Romero60% | $29 → $32 | Upgrade | Neutral → Overweight | Get Alert |
08/22/2023 | Buy Now | 82.61% | Cantor Fitzgerald | Sarah James50% | → $42 | Reiterates | Overweight → Overweight | Get Alert |
08/07/2023 | Buy Now | 26.09% | JP Morgan | Tessa Romero60% | $28 → $29 | Maintains | Neutral | Get Alert |
08/03/2023 | Buy Now | 65.22% | Canaccord Genuity | Sumant Kulkarni43% | $39 → $38 | Maintains | Buy | Get Alert |
08/03/2023 | Buy Now | 30.44% | Morgan Stanley | Jeffrey Hung51% | $30 → $30 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
08/03/2023 | Buy Now | 8.7% | Oppenheimer | Jay Olson60% | → $25 | Reiterates | Perform → Perform | Get Alert |
08/03/2023 | Buy Now | 43.48% | HC Wainwright & Co. | Andrew Fein61% | → $33 | Reiterates | Buy → Buy | Get Alert |
07/28/2023 | Buy Now | 8.7% | Oppenheimer | Jay Olson60% | $23 → $25 | Maintains | Perform | Get Alert |
07/17/2023 | Buy Now | 69.57% | Canaccord Genuity | Sumant Kulkarni43% | $28 → $39 | Maintains | Buy | Get Alert |
07/17/2023 | Buy Now | 82.61% | Cantor Fitzgerald | Sarah James50% | $36 → $42 | Maintains | Overweight | Get Alert |
07/14/2023 | Buy Now | 43.48% | RBC Capital | Gregory Renza50% | $28 → $33 | Maintains | Outperform | Get Alert |
07/14/2023 | Buy Now | 17.39% | Citigroup | Neena Bitritto-Garg58% | $21.6 → $27 | Maintains | Neutral | Get Alert |
07/14/2023 | Buy Now | 30.44% | Morgan Stanley | Jeffrey Hung51% | $21 → $30 | Maintains | Equal-Weight | Get Alert |
07/14/2023 | Buy Now | 69.57% | JMP Securities | Jason Butler52% | $31 → $39 | Maintains | Market Outperform | Get Alert |
07/14/2023 | Buy Now | — | Oppenheimer | Jay Olson60% | $20 → $23 | Maintains | Perform | Get Alert |
07/14/2023 | Buy Now | 43.48% | HC Wainwright & Co. | Andrew Fein61% | $28 → $33 | Maintains | Buy | Get Alert |
07/11/2023 | Buy Now | -8.69% | Morgan Stanley | Jeffrey Hung51% | $20 → $21 | Maintains | Equal-Weight | Get Alert |
06/14/2023 | Buy Now | 34.78% | JMP Securities | Jason Butler52% | $23 → $31 | Maintains | Market Outperform | Get Alert |
06/14/2023 | Buy Now | -13.04% | Mizuho | Uy Ear61% | → $20 | Reiterates | Neutral → Neutral | Get Alert |
The latest price target for ACADIA Pharmaceuticals (NASDAQ:ACAD) was reported by JP Morgan on June 6, 2025. The analyst firm set a price target for $30.00 expecting ACAD to rise to within 12 months (a possible 30.44% upside). 31 analyst firms have reported ratings in the last year.
The latest analyst rating for ACADIA Pharmaceuticals (NASDAQ:ACAD) was provided by JP Morgan, and ACADIA Pharmaceuticals maintained their overweight rating.
The last upgrade for ACADIA Pharmaceuticals Inc happened on May 21, 2025 when Deutsche Bank raised their price target to $35. Deutsche Bank previously had a hold for ACADIA Pharmaceuticals Inc.
The last downgrade for ACADIA Pharmaceuticals Inc happened on January 3, 2025 when Guggenheim changed their price target from $20 to $20 for ACADIA Pharmaceuticals Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ACADIA Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ACADIA Pharmaceuticals was filed on June 6, 2025 so you should expect the next rating to be made available sometime around June 6, 2026.
While ratings are subjective and will change, the latest ACADIA Pharmaceuticals (ACAD) rating was a maintained with a price target of $26.00 to $30.00. The current price ACADIA Pharmaceuticals (ACAD) is trading at is $23.00, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.